chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Day after vaccination, patient reports intermittent fevers (Tmax 104F), neck pain that radiates down her back, and is interacting a lot less than usual, The following day, she was unable to walk at all and required being carried to use the bathroom. Patient denies and fevers, cough, gi distress. She does states that she is not feeling short of breath at this time, but is having weakness in her hands as well as her legs. Additionally patient states that she has been having chest pain today that comes and goes.  On neuro exam Mental status: Appears to be distressed due to photophobia.  Lethargy, however easily arousable, able to have a conversation, attention intact to spelling "globe" backwards, intact to high and low frequency words. Able to name and repeat.  Speech: Mild dysphonia  Cranial Nerves:  II: Pupils equal, round reactive  III/IV/VI: EOMI. Pupils move in all four cardinal directions  VII: Face symmetric when talking, however limited effort to excursion on command  VIII: Responds to voice  IX/X: Voice normal  XI: Turns head side-to-side  XII: Tongue midline   Motor: Normal bulk and tone. Resistance met to passive motion of BLE  RUE/LUE: shoulder abduction 4/5, elbow flexion/extension 5/5, wrist flexion/extension with give-way weakness up to 4+/5, finger flexor 4/4  RLE/LLE: On command, 0/5 -however able to support her legs in a flexed position bilaterally, with encouragement 5/5 on dorsiflexion.  Able to support her weight on her legs, however does not walk slowly sits back on the bed.  Sensory: Intact to light touch, proprioception intact  Coordination: No obvious dysmetria on FNF testing  DTR: 2+ brachioradialis, bicep, patellar, ankle b/l.  Plantars mute.  Absent pathological reflexes: Hoffman, cross adductor
Had chills, slight fever, diarrheafor a few days.  Then headaches set in .  Have several headaches a day.  17 days since my vaccine and I've had several a day every day since.  I WILL NOT BE TAKING A BOOSTER.
-burning, very dry, and itchy FACE rash (over the cheeks and forehead) that started 1 day after vaccine and lasted for ~5 days. -rash on arm around injection site, red and very itchy for 7 days -headache, low fever, chills, and sweats for 2 days
Significant swelling and erythema from shoulder to elbow 48 hours after vaccine.  Firm, painful.  Keflex given as patient leaving country without ability to follow up.
Pt states (L) arm was sore at injection site the next day then pain went away. 3 - 4 days later, it became sore again with distant pain and "burning feeling". By 10/11/15, his whole arm and upper back were affected and he is still in pain. He went to doctor 10/14/15 and was resolved VICODIN, prednisone and cyclobenzaprine with slight relief. Pt states that last year after receiving his flu shot, the same thing happened, but they never reported it.
Dizzy; diarrhea; nausea; fever; tired; This is a spontaneous report from a contactable consumer, the patient. A 62-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN620), via an unspecified route of administration in the left arm on 23Mar2021 at 09:45 (at the age of 62-years-old), as a single dose for COVID-19 immunisation. The patient had no medical history. The patient did not have any allergies to medications, food, or other products. Concomitant medication included cetirizine hydrochloride (ZYRTEC) for an unspecified indication from unknown date. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 24Mar2021, the patient experienced dizzy, diarrhea, nausea, fever and tired. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the reported events. The clinical outcome of the dizzy, diarrhea, nausea, fever and tired was recovering at the time of report.  No follow-up attempts are needed. No further information expected.
Erythema, edema at site of injection measuring 20 x 12 cm.
Sudden onset of fever of 102.8 and vomiting within 2 hours of receiving vaccine.
C/O dizziness, nausea, diffuse rash Total of BENADRYL 50 mg PO @ 10:12 AM. Pt tolerated well. Sent back to class. Rash resolved
pt had red whelps & small bruise on the right arm after immunization that went away after 2-3days. Pt has muscle pain in her right arm, up to shoulder, across back, down spine, and shoulder blade. She also has pain down right arm & right palm. The pain is constant, but worse at night. Pt is unable to sleep on her right side. Pt has tried aleve/ibuprofen/bengay/heat/and ice. But she is still having pain.
Fever / 102.7; Breathing difficult; This is a spontaneous report based on the information received by Pfizer (Manufacturer Report Number: USA 20191207961) from a non-contactable physician and a consumer.  This case was regarding a patient who received Otezla therapy for the treatment of psoriatic arthritis mutilans, psoriatic arthropathy and psoriasis vulgaris. Co-suspect medication Prevnar was included. On an unspecified date, Patient experienced the events 102.7 fever, trouble breathing while taking Otezla therapy. Physician stated that patient had no allergic reaction to Otezla. Outcome of the events 102.7 fever, trouble breathing was not recovered/not resolved. The causal relationship between the Otezla and the events 102. 7 fever, trouble breathing was not related. This case is linked to # (Pruritus) and # (Multiple fractures, Fall, Rib fracture). Initial information was received on 18Dec2019 via Otezla Support Program from a patient. Additional information was received on 27Jan2020 from physician in response to queries. Updated information was added. Co suspect medication, Clinical course information. Updated information was identified between double carets.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
voice sounded hoarse; experienced later a (partial) loss of her voice; could barely speak; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A 28 year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), administration date 27Mar2021 (Batch/Lot number: unknown) as dose 1, single for COVID-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DYSPHONIA (non-serious) with onset 28Mar2021, outcome "unknown", described as "voice sounded hoarse"; APHONIA (non-serious) with onset 28Mar2021, outcome "unknown", described as "experienced later a (partial) loss of her voice"; SPEECH DISORDER (non-serious) with onset 28Mar2021, outcome "unknown", described as "could barely speak".  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Systemic: Exhaustion / Lethargy-Severe, Systemic: Dementia symptoms loss track of time/places.-Severe, Systemic: Weakness-Severe
patient administered the Moderna monovalent vaccine instead of the bivalent booster dose; No adverse event; This spontaneous case was reported by an other health care professional and describes the occurrence of WRONG PRODUCT ADMINISTERED (patient administered the Moderna monovalent vaccine instead of the bivalent booster dose) and NO ADVERSE EVENT (No adverse event) in a 2-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. ASKU) for COVID-19 prophylaxis.     No Medical History information was reported.   On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form and first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced WRONG PRODUCT ADMINISTERED (patient administered the Moderna monovalent vaccine instead of the bivalent booster dose) and NO ADVERSE EVENT (No adverse event). At the time of the report, WRONG PRODUCT ADMINISTERED (patient administered the Moderna monovalent vaccine instead of the bivalent booster dose) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for WRONG PRODUCT ADMINISTERED (patient administered the Moderna monovalent vaccine instead of the bivalent booster dose).    No concomitant medications were provided by the reporter.  HCP reported that their facility only administers the Pfizer vaccine. However, they had a pediatric patient who chose to get the Moderna COVID-19 vaccine.   The patient received 2 doses of the Moderna COVID-19 vaccine for their primary series and went to urgent care recently to get a booster dose. The urgent care inadvertently administered the Moderna monovalent vaccine to this patient instead of the bivalent booster dose. They told the patient's parents that CDC has advised that the patient can receive the Moderna bivalent but 8 weeks after receiving the most recent dose. HCP did not have any patient information at this time or any details regarding the event.  No treatment medications were provided by the reporter.
Pt recv vax on 3/15/99; on 3/16/99 pt exp hives; tx=Benadryl
Routine titer checks of communicable disease titers found to be (-) for immunity against Varicella. Remembered siblings having chickenpox during childhood. Not sure of her status of having chickenpox. Had VARIVAX vaccination 7/30/10. Noted 16 days later scattered pinpoint red rash behind ears/neck/arms/chest. Saw PCP 8/16/10 was given SOLU MEDROL dose pack-rash noted some blistering. PCP unsure dermatitis vs varicella rash. Revisited PCP 8/23 given second SOLU MEDROL dose pack rash clearing.
After leaving the site after over 15 minutes, noticed splotchy area on neck. It went away on the 2-hour drive home. Today I am feeling some itchiness in random areas.  The mild pain at the injection site is gone.
bump at spot where injected/ local swelling on the injected arm; felt "funny", didn't feel quite right; This case was reported by a consumer via call center representative and described the occurrence of injection site swelling in a 83-year-old male patient who received Flu unspecified (Influenza vaccine) for prophylaxis.   The patient's past medical history included open heart surgery (had 3 years before reporting and now had prosthetic heart valves) and injection site swelling (on arm, after Covid shots). Previously administered products included pneumococcal vaccine with an associated reaction of peripheral swelling (whole injected arm swelled up, 4 years ago after having Pneumococcal booster and  had to go on prednisone for 5 days). Concurrent medical conditions included systemic lupus erythematosus (diagnosed 4 years ago). Concomitant products included hydroxychloroquine.   On an unknown date, the patient received Influenza vaccine. On an unknown date, less than a day after receiving Influenza vaccine, the patient experienced injection site swelling and feeling abnormal. On an unknown date, the outcome of the injection site swelling and feeling abnormal were recovered/resolved.   The reporter considered the injection site swelling and feeling abnormal to be related to Influenza vaccine.  Additional details were provided as follows: The patient self-reported this case. The age at vaccination was unknown. The patient had many vaccinations during his life. The patient mentioned that he had been getting the influenza/flu shot for years but a few times (not with every flu shot) he had local swelling on the injected arm or felt a bump at the spot where it had been injected and or he had felt "funny" did not feel quite right the next day. These events were so minor (and they self-resolved) that he did not even report them to his doctor. The patient did not provide any specific brand name of flu shot. The reporter did not want to involve the health care professional. The reporter did not consent to follow-up.
Within 8 hours broke out in hives over face, neck, trunk, limbs, palms and soles. Very pruritic. No lymph nodes, no fever. Area of injection, red, swollen, warm and tender
pt recvd vax & immed feeling of thick syrup forced into arm; discomfort gone w/in 7 minutes w/o treatment;
Arm rash, spreading down arm, redness, soreness. Patient saw primary Dr. - said patient had cellulitis. Patient was given a 10 day course of cefadroxil 500 mg. Patient is recovering. (Form was not available until 11/20/17 from our immunization dept.).
Subsequent to receiving one dose of varicella virus vaccine live the pt experienced a VZV breakthrough rash and a fever of 100F. It was noted that the pts siblings also experienced breakthrough VZV.
On day 9, patient developed redness, swelling, itching and heat. Symptoms worsened on 01-19-2021. Patient evaluated and given antibiotics. Symptoms greatly improved 01-20-2021.
4 year old with 13x18cm area of redness 2 days after vaccination at site of vaccination
0.3 ml dose was drawn up from Pediatric Pfizer vial and administered to patient. Patient received 0.3 ml of the Pediatric Pfizer vaccine instead of 0.3 ml of the adult Pfizer. The patient was notified as soon as it was discovered and advised to return to get 0.3ml of the 12+ adult pfizer vaccine. Patient returned on 12/03/2021 and was given the replacement dose of 0.3ml of the adult pfizer vaccine.on 12/03/2021. No adverse events were reported.
Rash to face and neck spreading to lower part of the body.  Appeared 4 hours after vaccine.
Couple weeks after second shot moderna vaccination I started getting throat pain and fast heart rate (palpitations). Initial suspicion was COVID-19 shu we did test and it came back negative. Then we did TSH test and it came low at 0.1. Two weeks after initial symptoms doc ordered full thyroid panel as he was suspecting hyperthyroidism. In full theories panel TSH came even lower at 0.03, free T4 2.2 and T3 at 172. Doctor referred me to endocrinologist for further diagnosis.   I?m keeping healthy over all and nothing has changed in my food habits, medical conditions or environment. Only major event was vaccination. In fact my TSH was 2.0 in latest test done on 02/10/2021.
muscle aches/pains, swelling/blistering/pain at injection site; states the injection site "swelled up to the size of a grapefruit"
Severe swelling/induration of deltoid region persisting 5 days after immunization.
WHEALS; This spontaneous report received from a patient concerned a male of unspecified age. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown) dose was not reported, administered on 20-MAY-2021 for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported. On 20-MAY-2021, the subject experienced wheals. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of wheals was not reported. This report was non-serious.
On 12/6/99, the pt broke out in a modified case of chickenpox. She was seen by a physician who noticed about 25 lesions. No further information is available.
slightly tender at the site of injection; sore arm; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 77 year-old female patient received bnt162b2 (BNT162B2), administration date 02Feb2021 (Lot number: EL3248) at the age of 77 years as dose 1, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: VACCINATION SITE PAIN (non-serious), outcome "unknown", described as "slightly tender at the site of injection"; PAIN IN EXTREMITY (non-serious), outcome "unknown", described as "sore arm". Additional information: The patient reported that she had no side effects with the 1st dose other than slightly tender at the site of injection, but she'd say basically no side effects and that she was unsure of the time of the sore arm with the first shot, she thought it was the next day.  No follow-up attempts are possible. No further information is expected.
Achey, sore, lethargic.  Starting to feel significant soreness in joints.  Particularly joints that have had old injuries or possible early stages of arthritis. Symptoms would ease back in for several weeks, particular with changing weather on the last round of this vaccine back in October of 2014.
72 yo man received Dose 1 Pfizer covid vaccine prior to acute admission.  On 5/11/21, patient was admitted for lower extremity osteomyelitis unrelated to vaccinations.  During this stay, Dose 2 Pfizer covid vaccine became due.  On 5/21/21 a vial of Pfizer covid vaccine was sent to the patient care area for administration.  The nurse drew up and administered 0.3 mL without first diluting.  The patient did not experience any adverse reactions or adverse effects as of 5/24/21.  Discharge is planned for 5/24/21.
Patients administered with vaccines that have undergone temperature excursion; Patients administered with vaccines that have undergone temperature excursion; This spontaneous case was reported by an other health care professional and describes the occurrence of POOR QUALITY PRODUCT ADMINISTERED (Patients administered with vaccines that have undergone temperature excursion) and PRODUCT TEMPERATURE EXCURSION ISSUE (Patients administered with vaccines that have undergone temperature excursion) in a 38-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 059H21A) for COVID-19 vaccination.     No Medical History information was reported.   On 09-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 05-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 28-Jan-2022, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 28-Jan-2022,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Patients administered with vaccines that have undergone temperature excursion). On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Patients administered with vaccines that have undergone temperature excursion). At the time of the report, POOR QUALITY PRODUCT ADMINISTERED (Patients administered with vaccines that have undergone temperature excursion) and PRODUCT TEMPERATURE EXCURSION ISSUE (Patients administered with vaccines that have undergone temperature excursion) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported.  No patient had reported any adverse events to date. Vaccine was thawed on 28-Jan-2022.  It was reported maximum or minimum temperatures reached as applicable on 28-Jan-2022 temperature (temp) range positive 34.7F to positive 41.2F, on 30-Jan-2022 temp range positive 34.7F to positive 41.2F which occurred for 48 hours; on 31-Jan-2022 temp range positive 34.7F to positive 41.2F for 12 hours and on 04-Feb-2022 temp range positive 35.2F to positive 41.7F for 12 hours.  No treatment information was reported.
Information has been received on 31-OCT-2018 regarding a case in litigation concerning a male patient (age unknown). The patient's medical history, concurrent conditions and concomitant medication use were not provided. The patient's healthcare provider, recommended and/or prescribed ZOSTAVAX to the patient for its intended purpose of permanent prevention and protection against shingles and zoster-related conditions. On or about 2015, the patient's healthcare provider administered the ZOSTAVAX vaccine to the patient. The patient was inoculated with the ZOSTAVAX vaccine to obtain permanent prevention and protection against shingles and zoster-related injuries. On or about 2015, the patient was treated by a healthcare provider at a hospital for shingles. The patient was diagnosed with shingles and/or other zoster-related injuries after and despite being inoculated with the ZOSTAVAX vaccine, and suffered serious physical, emotional, and economic damages as a result of the patient's injuries. The patient used the ZOSTAVAX vaccine for the permanent prevention of shingles and zoster-related injuries. The patient was diagnosed with shingles and/or other zoster-related injuries after and despite being inoculated with the ZOSTAVAX vaccine. As a direct and proximate result of the ZOSTAVAX vaccine, the patient has and will continue to suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; extensive medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs include care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; a diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions; lost wages; loss of earnings capacity; and other losses and damages. Additional information has been requested.
Still experiencing some side effects from the 2nd vaccine which got on 13-May-2021; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (Still experiencing some side effects from the 2nd vaccine which got on 13-May-2021) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 13-May-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION (Still experiencing some side effects from the 2nd vaccine which got on 13-May-2021). At the time of the report, VACCINATION COMPLICATION (Still experiencing some side effects from the 2nd vaccine which got on 13-May-2021) had not resolved.            No concomitant medication was provided by the reporter.  No treatment information was reported.
elevated t105; tx @ ER w/APAP, tempid bath @ home 11OCT95 Advil
Candida - Yeast infection internally and externally. Rashes, poor digestion, gas , diarrhea, constipation . weekly does of Diflucan, ongoing
This spontaneous report was report was received from a nurse, concerning a patient of unknown age and gender. The patient's medical history, concurrent conditions, drug reactions, allergies and concomitant medications were not reported. On an unknown date, the patient was vaccinated with an improperly stored PROQUAD for prophylaxis, albumin status rHA, lot #R003292 and expiration date 31-JUL-2019 (strength, dose, route of administration and frequency were not reported). No adverse symptoms were reported. The temperature excursion was reported as 8°F, during a time frame of 2 hours. It was reported that there was a previous temperature excursion. It was also informed by the nurse, that there was a temperature excursion reported as 8°F during a time frame of 1 hour and no previous temperature of excursion was provided (conflicting information). A digital data logger was involved.